TriSalus Life Sciences, Inc.
TriSalus Life Sciences, Inc. (TLSI) Insider Trading
Form 4 buy vs sell counts, ratio, and sentiment — switch this quarter or last 12 months; chart and transactions below.
SEC EDGAR · FMP · TLSI · as of Jun 8, 2026
Activity summary
Buy transactions
6
P-Purchase only
Sell transactions
14
12 Months
Buy/Sell ratio
0.43
Buy/Sell (by trades)
Overall sentiment
TriSalus Life Sciences, Inc. insiders have been primarily selling shares over the past 12 Months. Selling activity is often driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment toward the company.
▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · Buy = P-Purchase only · Sell = S-Sale only
As of Jun 8, 2026
TLSI insider buying and selling by quarter
TLSI insider selling · TLSI insider buying stocks · quarterly insider activity
Mobile shows last 4Q · Desktop shows full 8Q
▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · last 8 quarters
As of Jun 8, 2026
Active insiders
Most active in past 12 months · TLSI ceo insider trading
Showing all insiders · Click a card to filter the transactions table below
▸ Aggregated from reportingName · top 5 by trade count (12M) · no extra API
Recent insider transactions
TLSI executive sell shares · TLSI board member insider trading · TLSI insider trading SEC filing
Scroll horizontally to see all columns
| Date | Insider | Type | Shares | Value | Filing |
|---|---|---|---|---|---|
| May 15, 2026 | Marshak Richard Chief Commercial Officer | Sale | 543 | $1K | Form 4 |
| May 15, 2026 | Wahlstrom Mats Director | Purchase | 60,000 | $152K | Form 4 |
| May 15, 2026 | Stansky Michael P Director | Purchase | 410,000 | $1.02M⚡ | Form 4 |
| May 15, 2026 | Stansky Michael P Director | Purchase | 200,000 | $500K | Form 4 |
| May 15, 2026 | Szela Mary T CEO and President · Director | Purchase | 39,682 | $103K | Form 4 |
| May 15, 2026 | Patience David CFO | Purchase | 7,100 | $17K | Form 4 |
| May 15, 2026 | Gordon Gary B. Director | Purchase | 10,000 | $25K | Form 4 |
| May 14, 2026 | HICKS KERRY R Director | Award | 28,201 | — | Form 4 |
| May 14, 2026 | Wahlstrom Mats Director | Award | 34,226 | — | Form 4 |
| May 14, 2026 | Wahlstrom Mats Director | Award | 37,602 | — | Form 4 |
| May 14, 2026 | Gordon Gary B. Director | Award | 24,553 | — | Form 4 |
| May 14, 2026 | Gordon Gary B. Director | Award | 28,201 | — | Form 4 |
| May 14, 2026 | MATLIN DAVID J Director | Award | 23,065 | — | Form 4 |
| May 14, 2026 | MATLIN DAVID J Director | Award | 28,201 | — | Form 4 |
| May 14, 2026 | Valle William Director | Award | 24,553 | — | Form 4 |
| May 14, 2026 | Valle William Director | Award | 28,201 | — | Form 4 |
| May 14, 2026 | Stansky Michael P Director | Award | 20,089 | — | Form 4 |
| May 14, 2026 | Stansky Michael P Director | Award | 23,501 | — | Form 4 |
| Jul 31, 2025 | Frankenius Equity AB 10 percent owner | Other | 759,000 | — | Form 4 |
| Jul 31, 2025 | MATLIN DAVID J Director | Other | 330,000 | — | Form 4 |
| Mar 11, 2026 | Devlin Jodi Chief of Clinical Operations | Sale | 1,162 | $5K | Form 4 |
| Mar 12, 2026 | Devlin Jodi Chief of Clinical Operations | Sale | 1,772 | $7K | Form 4 |
| Mar 16, 2026 | Devlin Jodi Chief of Clinical Operations | Sale | 273 | $1K | Form 4 |
| Mar 11, 2026 | Cox Bryan F. Chief of Research | Sale | 1,138 | $5K | Form 4 |
| Mar 12, 2026 | Cox Bryan F. Chief of Research | Sale | 1,467 | $6K | Form 4 |
Marshak Richard
Chief Commercial Officer
Date
May 15
Shares
543
Price
$2.67
Value
$1K
Stansky Michael P
Director
Date
May 15
Shares
410,000
Price
$2.50
Value
$1.02M ⚡
Szela Mary T
CEO and President · Director
Date
May 15
Shares
39,682
Price
$2.59
Value
$103K
Devlin Jodi
Chief of Clinical Operations
Date
Mar 11
Shares
1,162
Price
$4.13
Value
$5K
Devlin Jodi
Chief of Clinical Operations
Date
Mar 12
Shares
1,772
Price
$4.09
Value
$7K
Devlin Jodi
Chief of Clinical Operations
Date
Mar 16
Shares
273
Price
$4.12
Value
$1K
⚡ = value ≥ $1M · Award/Option price shows — · formType=4 · securityName=Common Stock · url → sec.gov/Archives/edgar
▸ Source: SEC EDGAR · Form 4 filings · ⚡ = value ≥ $1M · Award/Option price shows —
About TLSI insider trading
TLSI insider trades
TriSalus Life Sciences, Inc. (TLSI) insider trading data is sourced from SEC Form 4 filings submitted by corporate insiders, including Stansky Michael P (Director), Szela Mary T (CEO and President · Director), Marshak Richard (Chief Commercial Officer). Over the past 12 months, 5 insiders have filed transactions with the SEC. TLSI insiders have been primarily selling, which may reflect pre-scheduled Rule 10b5-1 plan executions.
For TriSalus Life Sciences, Inc.'s institutional ownership breakdown and insider ownership percentage, see the Ownership tab → Ownership tab →
Frequently asked questions
TLSI insider trading · 5 questionsThe insiders of TriSalus Life Sciences, Inc. (TLSI) include executives and directors such as Stansky Michael P (Director), Szela Mary T (CEO and President · Director), Marshak Richard (Chief Commercial Officer), among others. Over the past 12 months, 5 insiders have filed Form 4 transactions with the SEC. Insider transactions are required to be reported within 2 business days of the trade date.
▸ Source: FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · acquisitionOrDisposition A=Buy, D=Sell · RSU vesting (M-Exempt) excluded from sentiment bar · As of Jun 8, 2026